Table 2 Cox regression analyses of overall and progression-free survivals in the training data set.

From: Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma

Univariate analysis

Progression-free survival

Overall survival

HR (95% CI)

P-value

HR (95% CI)

P-value

Age

   <65 years

1

 

1

 

   ≥65 years

0.6 (0.33–1.11)

0.102

0.55 (0.28–1.08)

0.081

Sex

   Male

1

 

1

 

   Female

0.85 (0.44–1.62)

0.617

0.77 (0.38–1.56)

0.464

KPS

   90

1

 

1

 

   80

0.97 (0.55–1.7)

0.903

1 (0.54–1.86)

0.989

   70

5.21 (1.16–23.47)

0.032

3.38 (0.77–14.88)

0.107

Location

   Upper

1

 

1

 

   Middle

0.89 (0.5–1.57)

0.679

0.82 (0.44–1.52)

0.527

   Lower

2.87 (0.98–8.37)

0.054

1.15 (0.34–3.9)

0.825

Length

   <5 cm

1

 

1

 

   ≥5 cm

1.31 (0.75–2.26)

0.342

1.51 (0.83–2.76)

0.178

Clinical T stage

   T2

1

 

1

 

   T3

1.61 (0.67–3.88)

0.284

1.44 (0.55–3.76)

0.455

   T4

1.89 (0.72–4.9)

0.194

1.81 (0.64–5.12)

0.262

TNM sixth edition

   IIb

1

 

1

 

   III

1.41 (0.51–3.93)

0.509

1.66 (0.51–5.38)

0.398

Response

   CR

1

 

1

 

   PR

1.08 (0.5–2.35)

0.837

1.46 (0.56–3.78)

0.435

   SD

2.72 (1.07–6.92)

0.035

4.21 (1.42–12.46)

0.01

Compactness

   Low risk

1

 

1

 

   Moderate risk

1.61 (0.83–3.13)

0.156

2.02 (0.98–4.16)

0.056

   High risk

3.69 (1.87–7.28)

<0.001

2.87 (1.38–5.97)

0.005

Multivariate analysis

Age

   <65 years

1

 

1

 

   ≥65 years

0.41 (0.19–0.87)

0.02

0.48 (0.21–1.07)

0.072

Sex

   Male

1

 

1

 

Female

1.37 (0.65–2.91)

0.409

1.31 (0.57–3.01)

0.521

KPS

   90

1

 

1

 

   80

0.86 (0.45–1.62)

0.635

1.05 (0.53–2.07)

0.891

   70

4.11 (0.82–20.61)

0.086

2.58 (0.5–13.46)

0.26

Location

   Upper

1

 

1

 

   Middle

1.17 (0.63–2.17)

0.615

1.1 (0.57–2.12)

0.781

   Lower

5.21 (1.22–22.31)

0.026

0.95 (0.16–5.54)

0.952

Length

   <5 cm

1

 

1

 

   ≥5 cm

1.49 (0.79–2.81)

0.215

1.54 (0.78–3.05)

0.212

TNM sixth edition

   IIb

1

 

1

 

   III

1.75 (0.56–5.51)

0.337

1.71 (0.47–6.28)

0.418

Response

   CR

1

 

1

 

   PR

1.23 (0.54–2.8)

0.615

1.48 (0.53–4.13)

0.458

   SD

4.4 (1.56–12.43)

0.005

6.65 (2.06–21.49)

0.002

Compactness

   Low risk

1

 

1

 

   Moderate risk

2.48 (1.21–5.09)

0.013

2.73 (1.27–5.87)

0.01

   High risk

3.37 (1.55–7.31)

0.002

3.13 (1.25–7.83)

0.015

  1. HR: hazard ratio, CI: confidence interval, KPS: Karnofsky Performance Score, CR: complete response, PR: partial response, SD: stable disease.